Pharma group UCB raises profit forecast after strong first half-year

Belgian pharmaceutical group UCB saw its turnover rise to 3.49 billion euros in the first half of the year, an increase of 25 per cent year-on-year. It has raised its financial forecasts for 2025, with turnover expected to reach at least 7 billion euros, the company said in a press release.

UCB’s net sales rose 26 per cent to 3.32 billion euros. Underlying profitability (adjusted EBITDA) also increased to 1.03 billion euros, a jump of 58 per cent.

“Our performance in the first half of 2025 showcases our ambition and execution capabilities for robust and sustainable growth over the next decade and beyond,” said CEO Jean-Christophe Tellier. 

“It underscores our unwavering commitment to ensuring people with severe diseases can live the best life that they can, as free as possible from challenges of disease.”

The company, based in Brussels, produces drugs including Bimzelx, Rystiggo, Zilbrysq, Evenity and Fintepla. 

^{Staff at UCB's Biomanufacturing Operations Center in Braine l'Alleud, April 2024 © BELGA PHOTO LAURIE DIEFFEMBACQ}

Related news

Proximus lowers profit forecast for 2025

Telecom operator Proximus is lowering its profit forecast for this year after a mixed second quarter. Presenting its half-year results on Friday...

belganewsagency.eu

Aviation overtakes pharma industry as most sought-after job sector in Belgium

The pharmaceutical industry has lost its long-held position as Belgium's most attractive employment sector, overtaken this year by aviation. This...

belganewsagency.eu